HZNP — Horizon Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Horizon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	R2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,208	1,300	2,200	3,226	3,629
Cost of Revenue
Gross Profit	816	938	1,668	2,432	2,709
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	1,170	1,232	1,742	2,683	3,012
Operating Profit	37.9	67.8	458	543	617
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-83.1	-20.2	402	463	527
Provision for Income Taxes
Net Income After Taxes	-75.8	573	390	534	521
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-38.4	573	390	534	521
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-38.4	595	390	534	521
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.344	3.14	2.31	2.88	2.83

Discover the metrics influencing Horizon Therapeutics's share price